Illness
Covid-19 • Review
Covid-19 is not an easy decision to bring it up on our blog. However, there has been nothing more disruptive than this virus in recent
Read More
1 September 2020
Blog
Tag: Covid Pfizer
welcome to the seventyone influential blog on crucial innovation. visit the numerous blog posts and use the article categories for similar technical topics.
naturally, we live with hundreds of gadgets and innovations at home and work. some modern innovations fit in your pocket, and some are as big as an iconic skyscraper. to illustrate the experience of prevailing trends, we have composed a small blog article about things that capture our eye.
hence, if you have a gadget, you want us to test it. we would be delighted to make ourselves available for a blog entry. however, we reserve the right to firmly refuse lucrative offers and invariably have to declare this for ethical reasons.
we earnestly hope you enjoy reading about new gadgets, needed services, dynamic simulations or features that catapult us into another world.
a modest donation to pursue our work is highly appreciated.
Since every vaccine in Switzerland must be authorised, it has to meet stringent safety, efficacy and quality requirements.
Swissmedic, the Swiss Agency for Therapeutic Products, has carefully assessed and authorised the mRNA vaccines against COVID-19. They are safe and effective. Several tens of thousands of people have received the vaccines in clinical trials.
Since their approval, several billion people have received these vaccines. They are also safe and effective for the elderly and those with chronic illnesses.
Experts will continue to monitor the safety and efficacy of the vaccines. The benefits of a vaccine must significantly outweigh the risks. Only then will the vaccine be recommended in Switzerland.
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 has demonstrated evidence of efficacy against COVID-19 in participants without prior proof of SARS-CoV-2 infection, based on the first interim efficacy analysis conducted on November 8, 2020, by an external, independent Data Monitoring Committee (DMC) from the Phase 3 clinical study.